Skip to content. | Skip to navigation

Personal tools

This is SunRain Plone Theme

Navigation

banner16
banner1
banner7
banner9
banner8
banner4
banner0
banner17
banner6
banner3
banner15
banner5
banner13
banner2
banner11
banner12
banner14
banner10
banner18
You are here: Home / Research / Other Activities / Brevetto 102018000010511

Brevetto 102018000010511

In data 22/11/2018 con numero 102018000010511 è stata depositata la domanda italiana di brevetto per invenzione dal titolo:

 “NUOVI PEPTIDI E PEPTIDOMIMETICI COME AGENTI POTENTI E MIRATI NELLA PREVENZIONE E NEL TRATTAMENTO DELL’INVASIONE E METASTASI TUMORALI “ 

"Novel peptides and peptidomimetics as potent targeted agents for prevention and treatment of tumor invasion and metastasis"


Inventore referente per il CNR: Maria Patrizia Stoppelli
Rif. CNR: 10568
Inventori: Stoppelli Maria Patrizia, Franco Paola, Iommelli Francesca per CNR; Carotenuto Alfonso, Grieco Paolo e Novellino Ettore per Università Federico II di Napoli  
Titolarità: 70% CNR, 30% Università Federico II di Napoli 

Abstract (english)

The invention concerns peptides and pharmaceutic compositions comprising peptides for the treatment of diseases and pathological conditions associated with altered cellular motility, migration and adhesion, including angiogenesis, invasion, tumor metastases, ophthalmic and cardiovascular pathologies. Furthermore, the invention concerns the use of peptides and derivatives thereof to inhibit metastases, preferably of fibrosarcomas, lung and mammary tumors. The peptides described here are to be administered to counteract also the pro-tumoral activity of tumor microenvironment in solid tumors. The invention also relates to the use of these peptides and derivatives thereof as inhibitors of platelet motility and protrusions during thrombus formation and in the prevention and treatment of acute thromboembolic pathologies. Furthermore, the invention concerns the use of peptides and derivatives thereof for the therapy of ophthalmic diseases, like allergic conjunctivitis, as anti-inflammatory and inhibitor of granulocyte migration. Finally, these peptides are efficacious in the therapy of age-related macular degeneration and diabetic retinopathy, characterised by neovascularisation and increased vascular permeability.